The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers

The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers

Gynecologic cancers account for approximately 11% of the newly diagnosed cancers in women in the United States and for 18% globally. The presence of tumor-infiltrating lymphocytes (TILs) influences the clinical outcome of cancer patients and immune checkpoint inhibitors (ICIs), including anti progra...

Full description

Bibliographic Details
Main Authors: Omid Kooshkaki, Afshin Derakhshani, Hossein Safarpour, Souzan Najafi, Parviz Vahedi, Oronzo Brunetti, Mitra Torabi, Parisa Lotfinejad, Angelo Virgilio Paradiso, Vito Racanelli, Nicola Silvestris, Behzad Baradaran
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:International Journal of Molecular Sciences
Subjects:
immune checkpoint inhibitors
PD-1 inhibitors
gynecologic cancers
PD-L1 inhibitors
Online Access:https://www.mdpi.com/1422-0067/21/14/5034

Internet

https://www.mdpi.com/1422-0067/21/14/5034

Similar Items